share_log

科濟藥業-B:翌日披露報表

CARSGEN-B: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Jun 12 10:09
Summary by Moomoo AI
科濟藥業-B(02171.HK)於2024年6月12日提交了翌日披露報表,披露其股份變動情況。報告顯示,公司在2024年5月31日至6月12日期間進行了股份回購,總計回購股份數目為1,498,000股,佔已發行股份的0.26%。回購的股份將擬註銷。此外,公司確認所有股份回購均已獲得董事會授權,並遵守相關上市規則及法律規定。根據最後一宗股份回購,公司將進入為期一個月的暫止期,直至2024年7月12日,在此期間不得發行新股或出售任何庫存股份。
科濟藥業-B(02171.HK)於2024年6月12日提交了翌日披露報表,披露其股份變動情況。報告顯示,公司在2024年5月31日至6月12日期間進行了股份回購,總計回購股份數目為1,498,000股,佔已發行股份的0.26%。回購的股份將擬註銷。此外,公司確認所有股份回購均已獲得董事會授權,並遵守相關上市規則及法律規定。根據最後一宗股份回購,公司將進入為期一個月的暫止期,直至2024年7月12日,在此期間不得發行新股或出售任何庫存股份。
Kozi Pharma-B (02171.HK) submitted its disclosure report the next day on June 12, 2024, disclosing its shareholding changes. The report shows that the company repurchased shares between May 31 and June 12, 2024, with a total of 1,498,000 shares repurchased, accounting for 0.26% of the issued shares. The repurchased shares will be cancelled. In addition, the company confirms that all share repurchases have been authorized by the board of directors and comply with relevant listing rules and laws. Based on the latest share repurchase, the company will enter into a one-month suspension period until July 12, 2024, during which no new shares may be issued or any existing shares sold.
Kozi Pharma-B (02171.HK) submitted its disclosure report the next day on June 12, 2024, disclosing its shareholding changes. The report shows that the company repurchased shares between May 31 and June 12, 2024, with a total of 1,498,000 shares repurchased, accounting for 0.26% of the issued shares. The repurchased shares will be cancelled. In addition, the company confirms that all share repurchases have been authorized by the board of directors and comply with relevant listing rules and laws. Based on the latest share repurchase, the company will enter into a one-month suspension period until July 12, 2024, during which no new shares may be issued or any existing shares sold.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more